Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief ...

Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

Among 198 patients with HIV who received a kidney from a deceased donor, risk of a safety event within a median of 2.2 years was similar between the two groups (adjusted HR 1.00, 95% CI 0.73-1.38), ...

Dr. Khatereh Ahmadi has 18 years' experience in biotech/pharma, currently leading MSD's Search and Evaluation Business Development team in Europe and the Middle East, focusing on oncology. She co ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Respiratory syncytial virus ...

There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific nanobody, ALX-0171. To characterize the therapeutic potential of ALX-0171, we exploited our ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

hTranslational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain iGenetics, Vaccines and Infectious Diseases, Healthcare Research ...